These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15157868)

  • 21. An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase.
    Ohkura K; Kawaguchi Y; Tatematsu Y; Uto Y; Hori H
    Anticancer Res; 2016 Jul; 36(7):3645-9. PubMed ID: 27354635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structures of active SRC kinase domain complexes.
    Breitenlechner CB; Kairies NA; Honold K; Scheiblich S; Koll H; Greiter E; Koch S; Schäfer W; Huber R; Engh RA
    J Mol Biol; 2005 Oct; 353(2):222-31. PubMed ID: 16168436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of inhibitors that bind to inactive kinase conformations.
    Liu Y; Gray NS
    Nat Chem Biol; 2006 Jul; 2(7):358-64. PubMed ID: 16783341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
    Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
    Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selectivity assessment of kinase inhibitors: strategies and challenges.
    Luo Y
    Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening.
    Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y
    J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Traditional Chinese medicine as dual guardians against hypertension and cancer?
    Tou WI; Chen CY
    J Biomol Struct Dyn; 2012; 30(3):299-317. PubMed ID: 22694277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Nat Rev Drug Discov; 2007 Oct; 6(10):834-48. PubMed ID: 17853901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress in the design of selective ATP-competitive kinase inhibitors].
    Deng XQ; Xiang ML; Jia R; Yang SY
    Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles.
    Sánchez C; Salas AP; Braña AF; Palomino M; Pineda-Lucena A; Carbajo RJ; Méndez C; Moris F; Salas JA
    Chem Commun (Camb); 2009 Jul; (27):4118-20. PubMed ID: 19568652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors.
    Awale M; Mohan CG
    J Mol Graph Model; 2008 Apr; 26(7):1169-78. PubMed ID: 18055238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taming the induced folding of drug-targeted kinases.
    Fernández A; Bazán S; Chen J
    Trends Pharmacol Sci; 2009 Feb; 30(2):66-71. PubMed ID: 19097649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erkitinib, a novel EGFR tyrosine kinase inhibitor screened using a ProteoChip system from a phytochemical library.
    Kim EY; Choi YJ; Park CW; Kang IC
    Biochem Biophys Res Commun; 2009 Nov; 389(3):415-9. PubMed ID: 19716804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.